Akebia Therapeutics to Conduct Investor Meetings at the Virtual U.S. Bancorp I BTIG Kidney Health ForumGlobeNewsWire · Oct 7, 2026
Akebia Therapeutics Announces Late-Breaking VOICE Trial Presentation and Posters on Akebia's Rare Kidney Pipeline at ASN Kidney Week 2026GlobeNewsWire · Oct 6, 2026
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire · Oct 1, 2026
Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney DiseasesGlobeNewsWire · Sep 14, 2026
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire · Sep 1, 2026
Akebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in BostonGlobeNewsWire · Sep 1, 2026Akebia Therapeutics, Inc., established in 2007 and headquartered in Cambridge, Massachusetts, is a biopharmaceutical company focused on discovering and commercializing therapies for patients suffering from kidney diseases. The firm's leading experimental drug, vadadustat, is an oral treatment currently in Phase III clinical trials. Its purpose is to address anemia resulting from chronic kidney disease (CKD) in adult patients, encompassing both those dependent on dialysis and those who are not.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 5, 2026 | -$0.04 | -$0.02 | Beat |
| May 7, 2026 | -$0.01 | -$0.03 | Miss |
| Feb 26, 2026 | -$0.03 | -$0.05 | Miss |
| Nov 10, 2025 | -$0.06 | $0.00 | Beat |
| Aug 7, 2025 | -$0.02 | $0.00 | Beat |
| May 8, 2025 | -$0.03 | $0.03 | Beat |